These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia. Furtado SV; Saikiran NA; Ghosal N; Hegde AS Pediatr Neurol; 2010 Jan; 42(1):72-4. PubMed ID: 20004869 [TBL] [Abstract][Full Text] [Related]
3. Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases. Kim YM; Seo GH; Kim YM; Choi JH; Yoo HW Endocr J; 2018 Mar; 65(3):307-315. PubMed ID: 29279457 [TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia and prolactinoma. Romijn JA Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588 [TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Outcomes of Prolactinomas in Children and Adolescents: A Large Retrospective Cohort Study. Yang Y; Ke X; Duan L; Yang H; Gong F; Pan H; Wang L; Zhu H J Clin Endocrinol Metab; 2024 Aug; 109(9):e1741-e1749. PubMed ID: 38164002 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis and drug therapy of prolactinoma. Ciccarelli E; Camanni F Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Akkus G; Karagun B; Yaldız HN; Evran M; Sert M; Tetiker T Horm Mol Biol Clin Investig; 2020 Dec; 42(2):153-157. PubMed ID: 34332519 [TBL] [Abstract][Full Text] [Related]
10. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS. Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432 [No Abstract] [Full Text] [Related]
11. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else. Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567 [TBL] [Abstract][Full Text] [Related]
12. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009 [TBL] [Abstract][Full Text] [Related]
13. Giant Pituitary Adenoma Presenting with Foster-Kennedy Syndrome in a 21-Year Old Ethiopian Patient: A Rarely Reported Phenomenon: A Case Report. Ayele B; Mengesha A; Wotiye A; Alemayehu Y Ethiop J Health Sci; 2020 Mar; 30(2):311-314. PubMed ID: 32165821 [TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia: pathophysiology and management. Verhelst J; Abs R Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552 [TBL] [Abstract][Full Text] [Related]
15. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study. Höfle G; Gasser R; Mohsenipour I; Finkenstedt G Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. Wang L; Wang X; Gong F; Pan H; Zhu H Front Endocrinol (Lausanne); 2023; 14():1285477. PubMed ID: 38093965 [TBL] [Abstract][Full Text] [Related]
17. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Becker G; Kocher M; Kortmann RD; Paulsen F; Jeremic B; Müller RP; Bamberg M Strahlenther Onkol; 2002 Apr; 178(4):173-86. PubMed ID: 12040754 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Petersenn S; Fleseriu M; Casanueva FF; Giustina A; Biermasz N; Biller BMK; Bronstein M; Chanson P; Fukuoka H; Gadelha M; Greenman Y; Gurnell M; Ho KKY; Honegger J; Ioachimescu AG; Kaiser UB; Karavitaki N; Katznelson L; Lodish M; Maiter D; Marcus HJ; McCormack A; Molitch M; Muir CA; Neggers S; Pereira AM; Pivonello R; Post K; Raverot G; Salvatori R; Samson SL; Shimon I; Spencer-Segal J; Vila G; Wass J; Melmed S Nat Rev Endocrinol; 2023 Dec; 19(12):722-740. PubMed ID: 37670148 [TBL] [Abstract][Full Text] [Related]
19. [Reversible blindness caused by an invasive prolactinoma]. Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749 [TBL] [Abstract][Full Text] [Related]
20. Giant prolactinoma in children and adolescents: a single-center experience and systematic review. Kumar S; Sarathi V; Lila AR; Sehemby M; Memon SS; Karlekar M; Sankhe S; Patil VA; Shah N; Bandgar T Pituitary; 2022 Dec; 25(6):819-830. PubMed ID: 35851929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]